[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eledon Pharmaceuticals Inc (ELDN)

Eledon Pharmaceuticals Inc (ELDN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 291,771
  • Shares Outstanding, K 77,188
  • Annual Sales, $ 0 K
  • Annual Income, $ -45,620 K
  • EBIT $ -86 M
  • EBITDA $ -89 M
  • 60-Month Beta 0.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.29

Options Overview Details

View History
  • Implied Volatility 120.33% (-27.01%)
  • Historical Volatility 59.33%
  • IV Percentile 16%
  • IV Rank 3.94%
  • IV High 1,025.49% on 08/11/25
  • IV Low 83.22% on 04/13/26
  • Expected Move (DTE 19) 1.25 (33.06%)
  • Put/Call Vol Ratio 43.55
  • Today's Volume 3,876
  • Volume Avg (30-Day) 931
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 22,037
  • Open Int (30-Day) 15,651
  • Expected Range 2.53 to 5.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.19
  • Number of Estimates 1
  • High Estimate $-0.19
  • Low Estimate $-0.19
  • Prior Year $-0.13
  • Growth Rate Est. (year over year) -46.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.38 +11.83%
on 06/11/26
4.49 -15.81%
on 06/22/26
-0.11 (-2.83%)
since 05/26/26
3-Month
2.68 +41.04%
on 03/30/26
4.49 -15.81%
on 06/22/26
+0.82 (+27.70%)
since 03/26/26
52-Week
1.35 +180.00%
on 11/21/25
4.60 -17.83%
on 11/03/25
+1.03 (+37.45%)
since 06/26/25

Most Recent Stories

More News
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial

Prospera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon’s planned Phase 3 trial of tegoprubart in kidney transplantation, expected to initiate in late...

NTRA : 261.91 (+0.45%)
ELDN : 3.78 (+3.56%)
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus

Tegoprubart-treated patients maintained higher mean eGFR over time, including a statistically significant approximately 12 mL/min/1.73 m² advantage at month 18 versus tacrolimus (74 vs. 61 mL/min/1.73...

ELDN : 3.78 (+3.56%)
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

– All 12 patients in study (100%) achieved insulin independence, producing their own insulin and no longer requiring exogenous insulin therapy to manage their T1D – All 12 patients also achieved...

ELDN : 3.78 (+3.56%)
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions

IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that updated results from an investigator-initiated trial being conducted...

ELDN : 3.78 (+3.56%)
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

IRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company will present new clinical data from its tegoprubart program...

ELDN : 3.78 (+3.56%)
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study  FDA Orphan Drug designation granted...

ELDN : 3.78 (+3.56%)
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results

Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase...

ELDN : 3.78 (+3.56%)
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine

- 12-patient cohort fully enrolled with an average time since transplant of approximately 8 months - 100% insulin independence achieved in 10 patients who are over 4 weeks post-transplant - No signs...

ELDN : 3.78 (+3.56%)
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation

IRVINE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc.  (“Eledon”) (NASDAQ: ELDN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug...

ELDN : 3.78 (+3.56%)
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference

IRVINE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steven Perrin,...

ELDN : 3.78 (+3.56%)

Business Summary

Eledon Pharmaceuticals Inc. is a clinical stage biotechnology company. It develop treatments for an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Eledon Pharmaceuticals Inc., formerly known as Novus Therapeutics Inc., is based in IRVINE, Calif.

See More

Key Turning Points

3rd Resistance Point 4.53
2nd Resistance Point 4.31
1st Resistance Point 4.05
Last Price 3.78
1st Support Level 3.57
2nd Support Level 3.35
3rd Support Level 3.09

See More

52-Week High 4.60
Last Price 3.78
Fibonacci 61.8% 3.36
Fibonacci 50% 2.97
Fibonacci 38.2% 2.59
52-Week Low 1.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.